Furthermore, the expression of IFI6 is elevated in the blood or platelet samples of patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary antiphospholipid syndrome, and MS [61–63]. Here, IFI6 is linked to myeloid sarcoma.